Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Non-cash Items (2016 - 2025)

Guided Therapeutics' Non-cash Items history spans 15 years, with the latest figure at $2.1 million for Q3 2025.

  • For Q3 2025, Non-cash Items fell 4.38% year-over-year to $2.1 million; the TTM value through Sep 2025 reached $2.1 million, down 4.38%, while the annual FY2024 figure was $1.9 million, 6.21% up from the prior year.
  • Non-cash Items for Q3 2025 was $2.1 million at Guided Therapeutics, down from $2.2 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $2.4 million in Q1 2025 and bottomed at -$224000.0 in Q2 2021.
  • The 5-year median for Non-cash Items is $1.9 million (2023), against an average of $1.7 million.
  • The largest YoY upside for Non-cash Items was 127.81% in 2021 against a maximum downside of 103.53% in 2021.
  • A 5-year view of Non-cash Items shows it stood at -$224000.0 in 2021, then surged by 688.43% to $1.3 million in 2022, then soared by 37.42% to $1.8 million in 2023, then increased by 6.21% to $1.9 million in 2024, then increased by 7.98% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Non-cash Items are $2.1 million (Q3 2025), $2.2 million (Q2 2025), and $2.4 million (Q1 2025).